Novo Nordisk follows Lilly into DTC obesity drug market
Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.
Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a ...
WLAX La Crosse on MSN15h
Lilly’s Purple Purse coming the the UWL stageThe University of La Crosse Theatre and Dance Department will bring their children’s production, Lilly’s Purple Plastic Purse ...
The reductions come at a time of significant growth overall for Lilly. and soon after the announcement of plans to build new ...
After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...
Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
Lilly Glaubach, 13, was killed while bicycling home in 2022 after a car slammed into her. The driver, David Chang, took off ...
Apple's and Eli Lilly's plans to expand manufacturing and development in the U.S. Earning updates from Home Depot and Cava.
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...
Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback